COV:CA:CDX-Covalon Technologies Ltd (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 1.2

Change

+0.05 (+4.35)%

Market Cap

USD 0.05B

Volume

6.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Covalon Technologies Ltd is engaged in the business of developing, licensing, and selling medical technologies. The Company generates its revenues through development contracts, licensing agreements, and distribution contracts and sales.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.16B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
CZO:CA Ceapro

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing COV:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.21% 43% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.21% 43% F 67% D+
Trailing 12 Months  
Capital Gain -40.00% 35% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.00% 35% F 41% F
Trailing 5 Years  
Capital Gain -76.42% 38% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.42% 38% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 0.34% 63% D 52% F
Dividend Return 0.34% 63% D 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.46% 42% F 45% F
Risk Adjusted Return 0.61% 63% D 52% F
Market Capitalization 0.05B 71% C- 77% C+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector